Skip to main content
. 2023 Jun 24;13(7):991. doi: 10.3390/brainsci13070991

Table 2.

Comparison of baseline data in patients with and without severe WMLs.

Variables Severe WMLs p Value
Yes, n =148 No, n = 174
Demographic characteristics
  Age, years 66.7 ± 12.5 63.0 ± 10.5 0.004
  Male, n (%) 89 (60.1) 96 (55.2) 0.369
Vascular risk factors, n (%)
  Hypertension 113 (76.4) 120 (69.0) 0.140
  Diabetes mellitus 61 (41.2) 66 (37.9) 0.548
  Hyperlipidemia 17 (11.5) 21 (12.1) 0.872
  Coronary heart disease 30 (20.3) 24 (13.8) 0.121
  Smoking 61 (41.2) 70 (40.2) 0.857
Clinical data
  Previous statin therapy, n (%) 48 (32.4) 52 (29.9) 0.622
  Previous antiplatelet therapy, n (%) 51 (34.5) 50 (28.7) 0.272
  Systolic blood pressure, mmHg 145.0 ± 24.4 137.9 ± 20.9 0.005
  Diastolic blood pressure, mmHg 83.4 ± 13.5 81.1 ± 11.9 0.106
  Baseline NIHSS, score 2.0 (0, 4.0) 2.0 (0, 4.0) 0.476
Stroke etiology, n (%) 0.012
  Large artery atherosclerosis 81 (54.7) 74 (42.5) 0.029
  Cardioembolic 25 (16.9) 21 (12.1) 0.218
  Small vessel occlusion 32 (21.6) 52 (29.9) 0.092
  Others 10 (6.8) 27 (15.5) 0.014
Laboratory data
  Total cholesterol, mmol/L 3.8 ± 0.9 3.9 ± 1.0 0.170
  Triglyceride, mmol/L 1.3 (1.0, 2.0) 1.4 (1.1, 2.2) 0.175
  Low density lipoprotein, mmol/L 1.9 (1.5, 2.5) 2.1 (1.6, 2.6) 0.147
  High density lipoprotein, mmol/L 1.0 (0.9, 1.2) 1.0 (0.9, 1.2) 0.278
  Homocysteine, mmol/L 15.1 ± 6.0 12.3 ± 4.3 0.001
  Baseline blood glucose, mmol/L 6.9 ± 2.3 6.8 ± 2.9 0.739
  Hs-CRP, mg/L 5.2 (2.6, 11.5) 4.0 (1.3, 12.1) 0.124
  CitH3, ng/mL 45.2 (17.8, 82.6) 19.6 (10.3, 46.5) 0.001

Abbreviations: CitH3, Citrullinated histone H3; Hs-CRP, hypersensitive C-reactive protein; NIHSS, National Institute of Health Stroke Scale; WMLs, white matter lesions. p indicated the statistical difference in the baseline data between groups. Informed consent was obtained from all subjects involved in the study. p indicated the statistical difference in the baseline data between groups.